CXL Ophthalmics is a clinical-stage company developing EpiSmart, a patented epithelium-preserving (Epi-On) cross-linking system designed to treat keratoconus without disrupting the corneal epithelium. EpiSmart (including Ribostat) enables minimally-invasive, simultaneous bilateral UV application intended to reduce discomfort and recovery time versus the current Epi-Off standard of care. The company emphasizes earlier intervention by enrolling patients upon diagnosis using tomographic imaging. CXLO completed a Phase 2 trial—the largest to date for corneal cross-linking—with 2,258 subjects, reporting visual acuity improvements similar to existing treatments and substantially enhanced safety and comfort. CXL Ophthalmics plans to initiate Phase 3 clinical trials and pursue a New Drug Application with the FDA. The recent Series A financing will support advancement of EpiSmart through those Phase 3 studies.

Total raised

$32M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2022